Pacira Biosciences Inc (NASDAQ:PCRX) Expected to Post Earnings of $0.42 Per Share

Share on StockTwits

Equities analysts predict that Pacira Biosciences Inc (NASDAQ:PCRX) will post earnings of $0.42 per share for the current quarter, Zacks reports. Seven analysts have issued estimates for Pacira Biosciences’ earnings, with the lowest EPS estimate coming in at $0.32 and the highest estimate coming in at $0.50. Pacira Biosciences reported earnings of $0.47 per share during the same quarter last year, which indicates a negative year over year growth rate of 10.6%. The firm is scheduled to issue its next earnings report on Thursday, February 27th.

According to Zacks, analysts expect that Pacira Biosciences will report full year earnings of $1.51 per share for the current year, with EPS estimates ranging from $1.39 to $1.60. For the next year, analysts anticipate that the company will post earnings of $2.12 per share, with EPS estimates ranging from $1.64 to $2.48. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Pacira Biosciences.

Pacira Biosciences (NASDAQ:PCRX) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.35. Pacira Biosciences had a net margin of 0.55% and a return on equity of 10.19%. The firm had revenue of $104.69 million during the quarter, compared to analysts’ expectations of $104.88 million. During the same period in the previous year, the company earned $0.31 earnings per share. The firm’s quarterly revenue was up 25.5% on a year-over-year basis.

A number of brokerages have commented on PCRX. BidaskClub raised shares of Pacira Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. BTIG Research began coverage on shares of Pacira Biosciences in a report on Wednesday, November 6th. They set a “buy” rating and a $56.00 target price for the company. Barclays upped their target price on shares of Pacira Biosciences from $52.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Cowen reaffirmed a “hold” rating and set a $41.00 target price on shares of Pacira Biosciences in a report on Thursday, November 7th. Finally, Jefferies Financial Group set a $60.00 target price on shares of Pacira Biosciences and gave the company a “buy” rating in a report on Tuesday, October 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $52.55.

In other Pacira Biosciences news, VP Lauren Bullaro Riker sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $43.59, for a total value of $217,950.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David M. Stack sold 70,000 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $44.47, for a total transaction of $3,112,900.00. Over the last ninety days, insiders have sold 76,176 shares of company stock valued at $3,382,759. 5.80% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Usca Ria LLC bought a new position in shares of Pacira Biosciences in the third quarter worth approximately $38,000. HM Payson & Co. bought a new position in shares of Pacira Biosciences during the second quarter worth $39,000. C M Bidwell & Associates Ltd. bought a new position in shares of Pacira Biosciences during the second quarter worth $44,000. LS Investment Advisors LLC bought a new position in shares of Pacira Biosciences during the third quarter worth $50,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Pacira Biosciences by 414.7% during the second quarter. Tower Research Capital LLC TRC now owns 1,436 shares of the company’s stock worth $63,000 after acquiring an additional 1,157 shares during the last quarter. Institutional investors and hedge funds own 99.13% of the company’s stock.

Shares of PCRX traded up $0.31 during mid-day trading on Monday, hitting $46.53. 31,688 shares of the company traded hands, compared to its average volume of 490,474. Pacira Biosciences has a 1 year low of $34.64 and a 1 year high of $50.30. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of 160.41, a P/E/G ratio of 2.07 and a beta of 1.17. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.32 and a current ratio of 3.95. The stock has a 50-day moving average price of $41.48 and a two-hundred day moving average price of $41.19.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Story: Market Perform

Get a free copy of the Zacks research report on Pacira Biosciences (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.